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Abstract: The MAPK/ERK (mitogen-activated protein kinase/extracellular signal- regulated kinase signaling pathway) 
and PI3K/Akt (lipid kinase phoshoinositide-3-kinase signaling pathway) play an important role in transmission of cell 
signals through transduction systems as ligands, transmembrane receptors and cytoplasmic secondary messengers to cell 
nucleus, where they influence the expression of genes that regulate important cellular processes: cell growth, proliferation 
and apoptosis. The genes, coding the signaling cascade proteins (RET, RAS, BRAF, PI3K, PTEN, AKT), are mutated or 
aberrantly expressed in thyroid cancer derived from follicular thyroid cell. Genetic and epigenetic alternations, concerning 
MAPK/ERK and PI3K/Akt signaling pathways, contribute to their activation and interaction in consequence of malignant 
follicular cell transformation. Moreover, it is additionally pointed out that genetic, as well as epigenetic DNA changing 
via aberrant methylation of several tumor suppressor and thyroid-specific genes is associated with tumor aggressiveness, 
being a jointly responsible mechanism for thyroid tumorigenesis. In the present manuscript the currently developed 
diagnostic and prognostic genetic/epigenetic markers are presented; the understanding of this molecular mechanism 
provides access to novel molecular therapeutic strategies.  
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INTRODUCTION 
  More than 10% of the population will develop nodules 
over their life, and a rise in thyroid cancer has also been 
observed in the last 3 decades, taking into account the 
diagnosis of 240,000 new cases in USA in the year 2004 [1]. 
So, thyroid nodules are very common and with the growing 
use of diagnostic imaging the number of thyroid nodules 
identified and undergoing further diagnostic evaluation as 
fine-needle aspiration biopsy (FNAB) is steadily growing; 
this technique is a safe, straightforward, sensitive, office-
based diagnostic procedure that represents an accepted 
standard of practice. Nevertheless, only 5% of all thyroid 
nodules harbor malignancy; therefore, preoperative 
differentiation of benign from malignant thyroid nodules is 
imperative. Its main limitation, however, remains the FNAB 
cytopathological category of indeterminate nodule, as 
definitive diagnosis of malignancy, requires a morphological 
finding of capsular and or vascular invasion by the tumor 
that is only identifiable in a resected thyroid specimen. 
Thyroid cancer constitutes only 1% of all epithelial 
malignancies worldwide and it represents 95% of all 
endocrine malignancies. It is currently unknown whether the 
increase in papillary thyroid cancer occurrence is real or is a 
false-positive result of improved diagnostic techniques and 
other procedures, or of increased screening for small nodules 
[2,3]. In the aspirate test of nodules after FNAB, 60-70% is 
considered benign, 5% is considered malignant, and 10-30%  
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is considered uncertain or suspected. Among suspected 
nodules, 20-25% eventually show thyroid cancer after 
surgery, and consequently 75-80% of patients in this 
subgroup will suffer an unnecessary thyroidectomy [4-6]. 
Although FNAB is the current gold-standard diagnostic test 
for thyroid nodules, it continues to be limited in the 
differential diagnosis of indeterminate lesions. In suspected 
cytolology, one can observe findings of diagnosis 
superposition among the following: hyperplasic nodules, 
follicular adenoma, cell adenoma of Hürthle cells, cancer of 
Hürthle cells and follicular variant of papillary carcinoma. 
The biology of thyroid cancer ranges from curable, 
incidental, well-differentiated micro-carcinomas to almost 
uniformly fatal poorly differentiated carcinomas. Despite 
extensive research to date, especially in genetic alterations, 
the scientific community has struggled to translate 
biomarkers into useful clinical tools and thus attains the full 
clinical potential for patients presenting indeterminate 
thyroid nodules. The conclusions following from all this 
information are that nowadays several markers have been 
used to improve diagnostic accuracy in the cases of uncertain 
or suspected cytological tests and mutation detection in 
clinical FNAB samples from thyroid nodules with the 
addition of BRAF mutation, and also the detection of RAS, 
RET/PTC, and PAX8/PPAR mutations, may also contribute 
to cancer diagnosis. BRAF, can also be used as a tool for 
tumor prognostication based in the recent evidences and in 
clinical practice [7,8]. On the other hand, the MAPK/ERK 
(mitogen-activated protein kinase/extracellular signal-
regulated kinase signaling pathway) and PI3K/Akt (lipid 
kinase phoshoinositide-3-kinase signaling pathway) play an 
important role in the transmission of cell signals through 
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and cytoplasmic secondary messengers to cell nucleus, 
where they influence the expression of genes that regulate 
important cellular processes: cell growth, proliferation and 
apoptosis. The genes, coding the signaling cascade proteins 
(RET, RAS, BRAF, PI3K, PTEN, AKT), are mutated or 
aberrantly expressed in thyroid cancer derived from 
follicular thyroid cell. Genetic and epigenetic alternations, 
concerning MAPK/ERK and PI3K/Akt signaling pathways, 
contribute to their activation and interaction in consequence 
of malignant follicular cell transformation. Moreover, it is 
additionally pointed out that genetic, as well as epigenetic 
DNA changing via  aberrant methylation of several tumor 
suppressor and thyroid-specific genes is associated with 
tumor aggressiveness, being a jointly responsible mechanism 
for thyroid tumorigenesis. The understanding of this 
molecular mechanism provides access to novel molecular 
prognostic and therapeutic strategies for inhibiting oncogenic 
activity of signaling pathways [7-14].  
RET/PTC 
  Constitutive activation of RET, RAS, and BRAF which 
are principle initiators of thyroid cancer. Activation of this 
tumor initiation pathway occurs in 70% of thyroid cancers. 
Paracentric reversal with the fusion of the protooncogene 
RET and the gene H4/D10S170 or the gene RFG/ELE1 
drives to the active way RET/PTC that codifies a protein 
with protein kinase activity in 50% of papillary thyroid 
cancers and also in benign nodules (29.2%), so this 
activation is not a marker of malignity.  
 RET/PTC is found in approximately in the 20% of adult 
sporadic papillary carcinomas, It can be detected in the 
sample test through inverse and chain reaction transcriptase 
of quantitative polymerase, which is not usual in clinical 
practice and is difficult to standardise. Thus, but its 
prevalence is highly variable between various observations, 
as consequence of the different sensitivity of the detection 
methods and also due to geographic variability and genetic 
heterogeneity [14,15]. All RET/PTC chimeric proteins 
activate the RAS-RAF-MAPK cascade and promote 
tumorigenesis. RET/PTC rearrangement occurs in patients 
with the history of radiation exposure (50–80%) and also in 
papillary carcinomas from children to young adults (40–
70%) where the PTCs that they presented have different 
characteristics with the classic papillary architecture, well 
prognostic and frequent rate of lymph node metastasis. So, 
the pattern of radiation-induced RET and NTRK1 
rearrangements in post-Chernobyl PTC biological has a 
phenotypic and clinical implications. [15-20]. The 
distribution of RET/PTC rearrangement within the tumor 
may be also heterogeneous, from clonal RET/PTC to be 
present only in a small fraction of tumor cells, nonclonal 
RET/PTC; this fact difficults also the diagnostic and the 
characterization of PTC tumors [19-21]. It can be detected in 
the sample test through inverse and chain reaction 
transcriptase of quantitative polymerase, which is not usual 
in clinical practice and is difficult to standardize. In clinical 
studies, 30-50% of papillary carcinomas are present 
RET/PTC in the cytological sample extracted by FNAB, but 
its analysis is difficult and may only be useful in 
combination with other markers [6,10,22].  
 The  rearrangement,  RET/PTC1 is the most common and 
comprises up to 60–70% of positive cases, whereas 
RET/PTC3 accounts for 20–30% and RET/PTC2 and other 
novel rearrangement types for less than 5% [20]. RET-PTC 
fusions have been reported at different percentage in 
different studies as well specified by the same author and 
only subjects (children and young adults) who have been 
exposed to radiations present a truly high incidence of this 
particular genetic alteration (Fig. 1). The RET/PTC3 was the 
most frequent after Chernobyl accident [20,21,23]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Percentages of genetic alterations found in radiated children or in spontaneous adult papillary thyroid carcinoma. 
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 Correlation  between  RET/PTC rearrangement and 
prognosis in PTC remains unclear. Some evidence suggests 
that the RET/PTC1 rearrangement type is associated with 
more favourable behaviour of PTC. In contrast to cases 
presented with RAS mutations that are associated with 
aggressive tumor phenotypes and poor prognosis. PTC cells 
carrying a BRAF mutation are more resistant to sorafenib 
treatment than PTC cells carrying RET/PTC rearrangement. 
Tumors harboring RET/PTC, especially RET/PTC1, have a 
very low probability of progression to poorly differentiated 
and anaplastic carcinomas [23].  
RAS 
  The activation of RAS constitutes a central mechanism in 
the development of papillary cancer in several cases; in 
cancer its mutations induce the hyperactivity of thyroid cells, 
though this phenomenon can also be observed in benign 
tumors [24-27].  
  Point mutations of the RAS genes are not restricted to a 
particular type of thyroid tumor and are found in follicular 
carcinomas, papillary carcinomas, and follicular adenomas. 
But,  RAS  mutations have been shown a trend to be 
associated to particular thyroid cancer histotypes. 
Specifically,  N-RAS with follicular variant PTC, follicular 
carcinoma and poorly differentiated thyroid carcinomas and 
perhaps  K-RAS with classical PTC [24]. The genetic 
alterations in the RAS/RAF/mitogen-activated protein kinase 
and phosphatidylinositol 3-kinase/Akt signaling pathways is 
present in the follicular variant of papillary thyroid 
carcinoma [25]. The frequency of RAS mutations reported in 
various series using comparable methodology utilizing DNA 
sequencing alone to define their role in thyroid 
tumorigenesis better of all three RAS genes (H-RAS, K-RAS, 
and N-RAS) in the same sporadic (non-radiation-induced) 
thyroid tumor. Although the frequency of RAS  point 
mutation in specific histologic types of benign and malignant 
thyroid tumors has been widely variable in the literature. 
RAS oncogene activation has been found in nearly 20% of 
benign and 40% of malignant thyroid tumors. The RAS 
mutations could only be identified in 3% samples with 
nodular goiter. Mutation of RAS gene was not present in the 
Hürthle cell adenomas. Most RAS  oncogenes occur in 
follicular type of tumors and have a higher incidence in 
follicular carcinomas. However, the reported prevalence of 
RAS mutations in papillary carcinomas was generally low. 
Several large studies in which tumors of various histologic 
types were analyzed using a highly sensitive screening 
method followed by direct sequencing to confirm mutations 
have also failed to identify any ras  mutations. The exact 
causes of the variability in RAS  mutation in papillary 
carcinomas remain unclear, they do not appear to harbor 
mutations of this oncogene in certain population. The 
significant association between RAS mutation and poorly or 
undifferentiated thyroid carcinomas of follicular cell 
derivation was confirmed in a recent series in papillary 
carcinomas [26, 27].  
 The  RAS  proto-oncogene encodes for a 21-kd protein 
(Ha-,  Ki- and N-RAS), which participates in signal 
transmission from the cell surface to the nucleus. RAS 
activation stimulates cell division and inhibits cell 
differentiation. The RAS  oncogene is activated by point 
mutations in codon 12 or 61 and sometimes in codon 13 or 
59. All three RAS genes are activated in thyroid cancers at a 
similar rate (11%–15%). However, RAS mutations are rare in 
solitary benign thyroid nodules. The monoclonal origin of 
these tumors implies somatic mutations in genes other than 
Ha-, Ki-, and N-RAS. Transgenic mice, in which RAS gene 
expression is specifically targeted to thyroid cells by the 
thyroglobulin gene promoter, have been reported to develop 
thyroid hyperplasia, papillary thyroid cancer and follicular 
adenomas or follicular carcinomas. Reduced expression of 
differentiation markers has been observed in these tumors, 
but the mechanism(s) via that mutated RAS  proteins 
stimulate cell division and inhibit cell differentiation, are 
poorly characterized. [24,25,28]. The role of RAS mutation 
in predicting more aggressive tumor behaviour is not well 
defined. Some evidence exists, however, that RAS mutations 
in invasive follicular and papillary carcinoma may correlate 
with more unfavourable prognosis, but this correlation is far 
from being conclusively established.  
  The study of the alterations and downstream-activated 
signals of the RAS/RAF-mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol 3-kinase/v-akt murine 
thymoma viral oncogene (Akt) (PI3K/Akt) signaling 
pathways. Tumors and matched normal thyroid samples 
were tested for RAS, for the v-RAF murine sarcoma viral 
oncogene (BRAF) substitution of valine (V) for glutamate 
(E) at codon 600 (the V600E mutation), for phosphatase and 
tensin homolog (PTEN), for catalytic phosphatidylinositol 3-
kinase p110 subunit alpha (PIK3CA), for AKT, and for the 
presence of rearranged during transfection (RET) proto-
oncogene/PTC (RET-PTC) and paired box-8 
(PAX8)/peroxisome proliferator-activated receptor gamma 
(PPAR) fusion protein (PAX8-PPAR) rearrangements by 
direct sequencing and reverse transcriptase-polymerases 
chain reaction analyses, respectively. Genetic alterations 
have been identified in 70% of follicular variant of PTCs. 
Activation of the MAPK and phosphatidylinositol 3-kinase 
pathways was observed in 74% and 22% of tumors, 
respectively. The alterations that were identified in the genes 
of the 2 pathways were mutually exclusive. Chromosomal 
RET-PTC and PAX8-PPAR rearrangements were observed 
in 20% and 17% of tumors, respectively. Thus, RET-PTC 
and PAX8-PPAR rearrangements and mutations of the 
neuroblastoma RAS viral oncogene homolog N-RAS at codon 
61 were the most common genetic alterations in follicular 
variant of PTCs. Activation of the MAPK pathway was a 
frequent event in follicular variant PTCs, and the 
phosphatidylinositol 3-kinase signaling pathway could be 
coactivated in RET-PTC tumors. These findings may have 
important therapeutic implication in patients with follicular 
variant of PTC [25]. Information obtained through 
cytological smears or anatomic samples permits the study of 
complex metabolic pathways, thus providing researchers 
with a high throughput tool for elucidating changes in the 
global expression patterns seen in tumor cells. This ability to 
investigate tumor biology would allow the selection of 
different drugs, considering the predominant altered 
pathways observed in these samples [29,30]. a. Compounds 
RAS antisense. These are small complementary DNA 
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useful as a substratum for ribonuclease to interfere in 
ribosomes, block the expression of genes, and inhibit the 
synthesis of protein. There are 2 drugs in development, ISIS 
2503 and ISIS 5132 [29]. b. Fenilacetat. This comes from the 
metabolism of phenylalanine and affects the translational 
process of RAS; it also decreases tumor growth and cellular 
differentiation, increases the 131I uptake and synthesis of 
thyroglobulin, and interferes in angiogenesis. In follicular 
cancer, fenilacetat would also act in synergy with 
transretinoic acid [29,30]. c. Farnesil transferase inhibition. 
It has been proved that this inhibits the accumulation in in 
vitro of RAS, thus reducing its signal of transduction. d. RAF 
inhibition. The RAF phosphorilated active MAP kinase 
promotes cell growth and decreases cell death; there is a 
compound  RAF antisense that is able to inhibit tumoral 
growth as much in in vitro as in in vivo [30].  
BRAF  
 BRAF is a central regulator of thyroid-specific 
differentiation and proliferative capacity in in vitro benign 
thyroid cell models. BRAF belongs to the RAF family of 
serine/threonine kinases and the V600E mutation results in 
constitutive activation in 45% of papillary thyroid 
carcinomas in adults. BRAF V600E mutation is typically 
found in papillary carcinomas with classical histology and in 
the tall cell variant, and is less common in the follicular 
variant of papillary carcinoma. This mutation can also be 
seen in anaplastic and poorly differentiated thyroid 
carcinomas arising from papillary carcinoma [31-34]. 
 BRAF mutations could occur in other exons of the gene. 
However the probability for this assumption is rather low 
This signaling cascade is not necessary in the initiation of 
tumor growth in thyroid follicular cells. This corresponds to 
a recent in vitro finding that suggests that the 
dedifferentiated phenotype of cold thyroid nodules is 
unlikely to be the result of activated RAS signaling. About 
95% of all mutations involve nucleotide 1799 and result in a 
substitution of valine to glutamate at residue 600 (V600E). 
This point mutation leads to constitutive activation of BRAF 
kinase and chronic stimulation of the MAPK pathway, and is 
tumorigenic for thyroid cells About 95% of all mutations 
involve nucleotide 1799 and result in a substitution of valine 
to glutamate at residue 600 (V600E). This point mutation 
leads to constitutive activation of BRAF kinase and chronic 
stimulation of the MAPK pathway, and is tumorigenic for 
thyroid cells [31,32]. Other and rare mechanisms of BRAF 
activation in thyroid papillary cancer include K601E point 
mutation, small in-frame insertions or deletions surrounding 
codon 600. 
  Moreover mice with transgenic expression of activated 
RAS targeted to the thyroid show thyroid abnormalities only 
with low incidence after long latency and develop papillary 
carcinomas rather than follicular tumors. Together with the 
recent finding of BRAF mutations in papillary thyroid 
carcinomas activation of RAS  or downstream signalling 
might not be a strong requisite for tumor progression and 
malignant transformation of follicular thyroid lesion. There 
are molecular events other than BRAF or RAS mutations that 
could constitutively activate the RAS/RAF/MEK/ ERK/MAP 
pathway. Such candidate molecules include other members 
of the RAF gene family such as RAF-1 or downstream genes 
such as ERG [33]. However, mutations in these genes have 
not been reported in neoplasia so far.  
  Detection and molecular characterization of a novel 
BRAF activated domain mutation in follicular variant of 
PTC; this finding reflects the importance to detect, in 
addition to the V600E mutation, other important activating 
BRAF mutations at least in follicular variant of papillar 
thyroid carcinoma [33]. The BRAF V600E mutation 
represents more than 90% of BRAF mutations found in 
thyroid cancer [34]. Based on evidence that BRAF is 
involved in the development of papillary carcinoma and in 
the progression to anaplastic cancer, BRAF is an attractive 
target in thyroid cancer, especially anaplastic and aggressive 
papillary subtypes where there is an urgent need for 
treatment.  BRAF V600E can induce thyroid cell 
transformation in in vitro and thyroid cancer in in vivo, 
confirming that this mutation is an oncogene for thyroid 
cancer [9,10]. BRAF V600E mutation is reported in 
approximately only 25% of anaplastic thyroid cancer 
suggesting that other genetic markers contribute to tumor 
progression. Studies that reported higher percentage of 
BRAF mutations in anaplastic thyroid cancer used poor 
sensitive detection technologies [31,35,36].  
 The  application  of  BRAF/V600E mutation analysis in 
FNAB specimens is more effective for thyroid nodules with 
malignant echographic features as compared with nodules 
without malignant echographic features. The use of the AS-
PCR is more valuable as compared with the direct DNA 
sequencing to refine the diagnosis in a clinical setting [37].  
  These findings might have some theoretical BRAF 
V600E mutation is generally accepted as a reliable 
prognostic marker for papillary carcinoma and more 
importantly, has been found to be an independent predictor 
of treatment failure and tumor recurrence, even in patients 
with low stage disease [38-41].  
  BRAF activation via BRAF V600E mutation in thyroid 
cells appears to lead to the alteration of function of sodium 
iodide symporter (NIS) and other genes metabolizing iodide, 
which is likely to be responsible for the decreased ability of 
tumors with BRAF  mutation to trap radioiodine and 
treatment failure of the recurrent disease [41-43]. The 
prognostic implications of BRAF mutation should be of 
particular importance in papillary microcarcinomas, which 
are incidentally discovered tumors. BRAF  V600E is the 
leading genetic event for PTC formation and the prevalence 
of BRAF mutation in clinically evident PTC in comparison 
to a set of and preoperatively discovered microcarcinomas 
the difference in BRAF V600E prevalence was in clinically 
evident PTC was 45% and in microcarcinomas 38.3%. It has 
been demonstrated that BRAF mutation in thyroid 
microcarcinomas correlates with either high rate of 
extrathyroidal tumor extension or lymph node metastasis 
[43]. In this sense, the combinational use of the mutation 
markers discussed above might be prognostically useful 
since  RAS mutation, RET/PTC, and likely PAX8/PPAR 
predict a less aggressive course of thyroid cancer than the 
BRAF mutation. Therefore, additional studies are needed to 
identify the highest risk patients within the BRAF mutation–
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  The incidence of BRAF V600E in anaplastic carcinomas 
is similar to that in early-stage well-differentiated tumors, 
suggesting that some anaplastic carcinomas develop from 
PTC and that BRAF signaling may be important in this 
process [47]. In human thyroid cancer, BRAF V600E is 
associated with vascular endothelial growth factor (VEGF) 
over-expression, which in turn is associated with increasing 
tumor stage and invasiveness [45-48]. BRAF V600E as a 
target may not be limited to only PTC with a BRAF 
activating mutation, since BRAF and other RAF kinases are 
activated by other oncogenes involved in follicular and 
papillary carcinoma [7]. Extensive angiogenesis in thyroid 
cancer cells has been observed. Thyroid tumors are highly 
vascular and follicular cancers that metastasize through 
blood vessels. Cancers expressed more VEGF mRNA and 
protein than did normal thyroid tissue. The mRNA 
expression patterns and immunohistochemical staining were 
similar between primary thyroid tumors and their lung or 
lymph node metastases. VEGF expression and secretion was 
increased in the differentiated thyroid cancers, follicular and 
papillary [46,48]. RAF kinases set off a mitogenic cascade of 
events that modulate gene expression by phosphorylation of 
transcription factors, which in turn affect cell proliferation 
and malignant transformation. There are 3 members of the 
RAF kinase family: ARAF,  BRAF and RAF-1. Additional 
evidence suggests that BRAF and RAF-1 take part in 
regulation of endothelial apoptosis and angiogenesis [49]. 
Sorafenib has demonstrated ability to inhibit RAF-1 and 
tumor cell line proliferation as well as tumor growth in 
multiple human tumor xenograft models. It was shown that 
sorafenib inhibits wild type (WT) BRAF and V600E mutant 
BRAF, as well as VEGFR-2, platelet-derived growth factor 
receptor (PDGFR)- and VEGFR-3. In this same study, 
sorafenib exhibited antitumor activity in xenograft models of 
human breast, colon, ovarian, lung, melanoma and pancreatic 
cancers, demonstrating effectiveness against tumors with 
mutations in KRAS and BRAF [50]. Sorafenib treatment also 
resulted in a 50 to 80% inhibition of microvessel area and 
density in a colon xenograft harboring mutated BRAF. These 
data suggested that sorafenib is both a RAF kinase and 
VEGFR inhibitor that targets the RAF/MEK/ERK cellular 
proliferation pathway and the receptor tyrosine kinases that 
support tumor angiogenesis [51]. RET is constitutively active 
in medullary and PTC. Medullary carcinoma has often 
metastasized before diagnosis, rendering it incurable. If 
initial measures for papillary carcinoma fail, these subjects 
too will be unable to be cured. For these subjects, there is no 
currently effective treatment. Mutations in RET in 
medullary, papillary and familial thyroid carcinoma make 
RET another promising target for the treatment of thyroid 
cancer [52,53]. Some authors showed that sorafenib inhibits 
the enzymatic function of the RET-PTC fusion protein and 
RET signaling, including receptor autophosphorylation and 
downstream signaling in a panel of human thyroid cancer 
cells with activating RET mutations along with RET/PTC 
and RET/multiple endocrine neoplasia (MEN) 2 oncogenes 
[54]. Sorafenib also targets signal transduction along the 
MAPK pathway and proliferation of tumor cells in BRAF 
V600E-positive thyroid cancer cell lines. Studies have 
shown that sorafenib can inhibit proliferation of poorly 
differentiated thyroid cancer cell lines regardless of whether 
they harbor BRAF V600E mutations [55]. Nowadays, the 
main criteria is that sorafenib mainly affects through 
inhibition of angiogenesis rather than specifically inhibiting 
the RAS pathway. Several phase II studies have proved this 
concept (e.g. melanoma and renal cancers phase clinical 
trials) [52,53]. Activating BRAF mutations in papillary 
thyroid carcinomas have been linked to aberrant methylation 
of several tumor-suppressor genes, including TIMP3, 
SLC5A8, DAPK and RAR2 [56,57]. Methylation of these 
genes correlated with signs of aggressive behavior in thyroid 
neoplasms, including extrathyroidal invasion, lymph node 
metastasis and advanced tumor stage at diagnosis, and their 
epigenetic silencing may be an important mechanism by 
which BRAF mutation promotes cancer progression [58,59]. 
Tyrosine kinase receptors bind for a wide variety of ligands 
and frequently are mutated and induce a constitutive 
activation such that a chimerical protein expression takes 
place in follicular cells in the domain of RET, as well as in 
other receptors. a. Receptors of vascular endothelial growth 
factor (VEGF). There are three receptors, 1,2 and 3, and it 
seems that 2 would prevail in the transduction pathway. 
There are studies that show high concentrations of VEGF in 
the serum of patients with metastases [7-10]. The drugs 
vandetanib, sorafenid, motesanib, sunitinib and exelisis are 
directed against RET; sorafenid and vandetanib against 
BRAF, and against VEGFR: axitinib, vandetanib, sorafenid 
and motesanib. b. Epidermal growth factor receptors (EGF). 
These constitute a superfamily of 4 related receptors [51], of 
which the most relevant is the Her2/neu that is over-
expressed in thyroid cancer. Taking into account the 
relevance of the 2 receptors VEGF and EGF, attention is 
now being dedicated to the possible blockade of the same in 
different levels of the inhibition of their m RNA with 
antisense compounds [51]. c. Antibodies. Monoclonal 
antibodies have been designed against the VEGF, and are 
able to reduce angiogenesis; some of them are in phase II or 
III of development. In experiments on animals, it has been 
proved that anti-VEGF antibodies block the angiogenesis 
and the expression of p53. Additionally, monoclonal 
antibodies have been developed against EGF, whose clinical 
studies in combination with chemotherapy or radiotherapy, 
are being given information about their possibilities. 
Herceptine is a high- affinity monoclonal antibody against 
the Her2/neu expressed by cancer, but herceptine not has 
been assayed in thyroid cancer [52]. d. Antagonists of the 
receptors. VEGF receptor inhibition through a selective 
antagonist of the receptor 2 is being used in studies in 
combination with placlitaxel in advanced cases. Paclitaxel in 
combination with campothectin has also been used because 
of its cytotoxic action in the cellular medullary carcinoma 
lines of the human thyroid [52]. e. Small molecules. These 
are small molecules that can interfere with receptors, with 
promising results, because they can block the tyrosine kinase 
activity of EGF. One of these molecules, ZD6474, manages 
by the oral route to inhibit angiogenesis through the 
inhibition of VEGF, but it has even been proved that it 
would inhibit the family of RET oncoproteins as much in in 
vitro as in in vivo, including RET/MEN2A, the RET/MEN2B 
and the RET/PTC3. This would suggest the potential of 
ZD6474 in the treatment of both medullary and papillary 
carcinoma [52, 58]. Treatment directed against tumoral 
angiogenesis. 1. Thalidomide. Designed initially as a 
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properties through its antiangiogenic actions of unknown 
origin. At present, a study gives information in a phase II 
assay. 2. Combretastatines. These are a protein family that is 
united to tubulin with antiangiogenic and antineoplasic 
properties; a study has been completed with combretastatine 
A4 in anaplastic carcinomas in which complete remission 
was observed in a patient [53, 59].  
PAX8/PEROXISOME-PROLIFERATOR-ACTIVATED 
RECEPTOR FUSION 
 PAX8/peroxisome-proliferator-activated  receptor fusion 
(PPAR) rearrangement is a ligand-dependent transcription 
factor and member of the nuclear receptor superfamily. It 
gained first attention as a key regulator of adipocyte 
differentiation, a process paralleled by cell cycle arrest and 
has been identified as a target for thiazolidinediones used as 
insulin sensitizers in the treatment of diabetes mellitus. A 
more general role of PPAR in regulation of cell 
differentiation and proliferation has been proposed on the 
basis that PPAR  agonists thiazolidinediones may prevent 
formation of neoplastic lesions in animal tumor models, 
exert growth-inhibitory effects in addition to reinduction of 
differentiation in several human cancers and in tumors 
induce changes in the cell cycle with growth arrest and 
apoptosis. PPAR has also been linked with thyroid 
pathology since the discovery of a PAX8/PPAR 
rearrangement in follicular thyroid carcinomas. This 
rearrangement, which represents a t(2;3)(q13;p25) 
translocation involving PAX8, an important transcription 
factor for thyroid differentiation and PPAR results in a 
fusion gene able to suppress wild-type PPAR in a dominant 
negative behaviour. PPAR has gained attention in various 
cancers, where impairment of PPAR function through 
mutations has been observed. Although little is known about 
the precise molecular mechanism of PAX-8/PPAR action, it 
is reasonable to assume that competition in transcriptional 
activation through DNA binding between overexpressed 
PPAR-fusion gene and wild-type PPAR could be the likely 
mechanism of dominant-negative PPAR inhibition.  
  The demonstration of the PAX8/PPAR fusion oncogene 
in a subset of follicular thyroid tumors provides a new and 
promising starting point to dissect the molecular genetic 
events involved in the development of this tumor form [60]. 
There are recent studies that prove the importance of genetic 
translocation between regions 3p25 and 2q13 when that 
translocation supposes the fusion of transcription thyroid 
factor PAX8 with the PPAR that is an oncogene. This 
fusion element increases cell growth, reduces apoptosis, and 
blocks the union of cellular lines to the surrounding tissues. 
It has been described mainly in follicular carcinoma, but is 
not a specific marker of this thyroid cancer [60].  
 PAX8/PPAR is found in 30–40% of conventional-type 
follicular carcinomas, and with lower prevalence in 
oncocytic carcinomas in a small fraction of follicular 
adenomas and occasionally in the follicular variant of 
papillary carcinoma. Tumors harboring PAX8/PPAR tend 
to present at a younger age and are smaller in size, have a 
solid/nested growth pattern, and more frequently reveal 
vascular invasion [7, 61].  
MicroRNA markers 
(miRNAs) are are a newly discovered class of endogenous 
short (18–24 nucleotides) noncoding RNAs. that  act as 
negative regulators of the protein-coding gene expression 
through the complementary binding to 30 untranslated 
region (UTR) of target mRNA, which lead to translational 
repression and inhibition of protein synthesis. miRNA 
expression is deregulated in many types of human cancers, 
including thyroid cancer [62,63]. Several studies have 
demonstrated that normal thyroid cells have a unique profile 
of miRNA expression and many miRNAs are dysregulated 
in thyroid cancer cells. A subset of these miRNAs, including 
miR-221, miR-222, miR- 146b, miR- 155, and miR- 187, has 
been consistently found to be upregulated in thyroid 
papillary carcinoma. As the most important innate immune 
receptors, toll-like receptors (TLRs) represent the first line of 
defense against pathogens. MiRNAs have emerged as 
important controllers of TLR signaling. Several miRNAs, 
induced by TLR activation in innate immune cells, target the 
3' untranslated regions of mRNAs encoding components of 
the TLR signaling system. miRNAs also function as an 
important link between the innate and adaptive immune 
systems, and their dysregulation may have a role in the 
pathogenesis of inflammatory diseases [64].  
 They  are  BRAF and RAS point mutations and RET/PTC 
and PAX8/PPAR rearrangements. Among other types of 
genetic alteration, miRNA markers appear to be the most 
promising for the diagnostic use at this time miRNAs [62]. 
  As many as 530 human miRNAs have been identified 
and this number is constantly increasing. miRNAs have a 
role in a wide variety of physiologic cellular processes, 
including differentiation, proliferation, and apoptosis. 
miRNA dysregulation is a common finding in malignancy, 
and there is mounting evidence supporting a role of miRNAs 
in carcinogenesis [62]. 
  Specific tumors exhibit unique expression profiles of 
miRNAs differentiating them from one another, more 
importantly from normal tissues. Several recent studies have 
utilized miRNA microarrays to demonstrate unique 
molecular expression signatures differentiating benign from 
malignant thyroid lesions, particularly PTC, which is the 
most common well-differentiated thyroid malignancy 
encountered in clinical practice. Four mutation types 
constitute the majority of known mutations occurring in 
papillary and follicular cancers and carry the highest impact 
on tumor diagnosis and prognostication. Specifically, 
miRNAs 21, 31, 146b, 187, 221, and 222 are differentially 
expressed in malignant and normal thyroid tissue [64]. 
Moreover, strong correlation was found between miRNA 
expression and somatic mutations found in this tumor type. 
Specifically, upregulation of miR-187, miR-146b, and miR-
155 was found to be significantly more pronounced in 
papillary carcinomas carrying RET/PTC rearrangements, a 
genetic event characteristically found in radiation-induced 
thyroid tumors. 
  Many miRNAs are expressed in cell type–specific 
manner and significantly overexpressed or down-regulated in 
tumors as compared to normal tissues, providing a rationale 
for their potential diagnostic use [65,66]. To date, FNAB 
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of the aspirated cells and is highly dependent on the 
expertise of the examiner. Follicular lesions are a subgroup 
of possible FNAB results that faces both the patient and the 
treating physician with a dilemma. On one hand, malignancy 
cannot be definitely diagnosed by FNAB; on the other hand, 
the actual final malignant pathology rate ranges between 
20% and 37%. An accurate diagnostic miRNA panel can 
bring a dramatic change in the decision process of such 
cases. miRNA quantification for differential diagnosis of 
thyroid neoplasms within aspiration biopsy samples is 
feasible and may improve the accuracy of FNAB cytology 
[65-70].  
  Deregulated miRNAs have been associated to genetic 
alterations; to specify also which specific type of mutations 
or rearrangements have been associated to. It would stress 
the fact that despite few miRNAs have been associated to 
some genetic mutations that additional and larger studies are 
warranted; for example there are few studies that do not find 
any association between BRAF mutations and any miRNAs 
[65]. One hundred percent specificity and 95% sensitivity 
were achieved by testing mir-221, and this may reduce the 
value of the other miRNAs in the panel. However, one must 
realize that thyroid neoplasms are variable and may represent 
a common phenotype of many genetic abnormalities. In 
larger cohorts of patients, these underlying genetic 
abnormalities may have an impact on miRNA expression 
[69,70]. At present, the exact role of miRNAs in 
carcinogenesis of tumors is yet to be elucidated. miRNAs 
regulate gene expression at the post-transcriptional level and 
thereby may control cellular processes such as 
developmental transitions, organ morphology, cell 
proliferation, and apoptosis. It is postulated that each 
miRNA regulates up to 100 different mRNAs and that more 
than10.000 mRNAs appear to be directly regulated by 
miRNAs [7]. In carcinogenesis, miRNAs can either regulate 
known oncogenes or tumor suppressor genes at the post-
transcriptional level or act themselves as oncogenes or tumor 
suppressor genes [66]. If up-regulation of these miRNA was 
found in thyroid cells after radiation exposure, it would 
suggest that miRNAs play a direct role in the generation of 
carcinogenic chromosomal rearrangements in human cells. 
However, none of these miRNAs were found to be up-
regulated either after 4 or 24 hours after exposure. This 
indicates that miRNAs are unlikely to participate directly in 
the generation of carcinogenic chromosomal rearrangements 
after radiation exposure, but more likely to play a role in the 
cellular response to radiation by modulating the expression 
of acute exposure of thyroid cells to -radiation results in 
several specific patterns of miRNA response and it is likely 
to affect other cell functions, such as DNA repair [68].  
Protein p53 
  Protein p53 is a codified phosphoprotein and a 
suppressor gene that is united to specific sequences of DNA 
regulating cell cycles, inhibiting cell division, repairing 
DNA and promoting apoptosis. Mutated forms are dominant 
and their half life is of hours instead of minutes which is the 
case with non-mutant forms; this allows protein p53 
detection by immunochemistry to be relatively easy. About 
50% of all cancers present mutations of protein p53, which 
thus constitute the most frequent genetic alteration in general 
cancer. Such mutations are observed in between 0-10% of 
papillary thyroid cancers, in 40% of only-slightly 
differentiated cancers, and in between 60-90% of anaplastic 
carcinomas. The presence of mutant protein p53 has been 
related to a worse prognostic of prognosis for thyroid 
cancers, but nowadays it is not thought that protein p53 may 
trigger the transformation of nodules from benign to 
malignant. This protein therefore has great potential as an 
indicator of prediction in little-differentiated cases or in 
anaplastic carcinomas [4,69,70], but not in the aspiration 
biopsy sample taken from it, and this suggests a sampling 
error, an inherent limitation of aspiration biopsy. Therefore, 
theoretically our assay may reach 100% accuracy if sampling 
accuracy is verified [4,71]. Many thyroid cancers have lost 
suppressor gene p53 expression because its mutation renders 
the gene inactive. The restoration of the native p53 way has 
been used in different experimental models and even in 
clinical assays. Some studies have proved that the restoration 
of the gene p53 protects transducted cells as well as the 
surrounding cells. Its effect is maintained through its 
antiangiogenic action, since it regulates, VEGF decreasing 
its activity and increasing trombospondin, which is a strong 
angiogenenic suppressant. Two recombinant adenoviruses 
have been used (Cre/loxP system): one contains the promoter 
expression of p53, and the other, two units. One of these is 
the gene E1A and the other is a low gene of cytomegalovirus 
promoter. The coinfection by the two adenoviruses leads to 
the arrest of viral replication if p53 is present [70,71]. The 
protein family Gadd45 (growth arrest and DNA damage-
inducible gene family), has been implicated in DNA 
replication and repair; a low concentration of Gadd45 has 
been shown in anaplasic carcinomas, as has the fact that the 
increase of Gadd45 mediated by adenoviruses significantly 
inhibits cellular growth [71]. High mobility group proteins 
(HMGI) are overexpressed in several malignant tumors; it 
has been proved that using adenoviruses that transport 
HMGI with an antisense orientation induces an apoptosis 
increase in the human cellular lines of anaplastic carcinoma, 
although not in human cells. Given such a generalised 
expression of these proteins in thyroid cancer, this strategy 
could be useful in the future [71].  
GALECTIN-3 
  Galectin-3, formerly known as L-14, gal3 macrophage 
galactose-specific lectin or HLBP14, is part of a family of 
lectines not integrins, that transports -galactoside, regulates 
growth, has cytostatic functions, transports lamininin, and 
intervenes in molecular adhesion, inflammation, the 
malignant transformation of nodules, and the development of 
metastases. It can be determined in the smear test through 
immunochemistry and western blotting. Galectin is 
expressed in thyroid cancer, and its distribution is 
cytoplasmtic and nuclear [72]. It was first detected in 
papillary carcinoma, and later in follicular carcinoma, as 
well as in medullary carcinoma [72,73]. It can be determined 
in cytogical samples or in surgical pieces through the 
commercial antibody for immunohystochemical method; it is 
overexpressed in the majority of follicular carcinomas and 
also in adenomas, between 1-72%, according to the 
accumulated results of 8 clinical series with several cases 
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reliably distinguish adenomas from carcinomas. 
Furthermore, galectin-3 might be able to represent a function 
in benign to malign nodule transformation [4]. The 
diagnostic accuracy of the positivity of galectin-3 for 
inmunohystochemistry presents a sensitivity of 86%, a 
specificity of 36%, a predictive positive value of 53%, and a 
predictive negative value of 75%; moreover, it has a 
diagnostic accuracy of 59%. It can be used, therefore, as a 
supplementary marker, and galectin-3 could be a good tool 
for guiding therapeutic decisions in patients with thyroid 
nodules and with FNAB results suggestive of follicular 
neoplasm. Nonetheless, the information available shows that 
nowadays galectin-3 has methodological flaws that preclude 
a definitive answer about its utility in the clinical setting. 
Serum concentrations of galectin-1 and -3 are relatively high 
in patients with thyroid malignancy, but there is a 
considerable overlap in serum galectin-3 concentrations 
among those patients with benign and malignant nodular 
thyroid disease and, to a lesser extent, among those with or 
without nodular thyroid disease [76]. The combined 
detection of galectin-3 and BRAF  V600E improves the 
diagnosis in FNAB with cytological findings that give rise to 
suspicions of papillary thyroid carcinoma; and this detection 
finds clinical application in selected cases. With the 
combined use of HBME-1 and galectin-3 in indeterminate 
FNABs, a 10% increase in sensitivity is achieved. These 
markers show excellent sensitivity and specificity and may 
improve the selection of patients for surgery [75,77].  
EPIGENETIC CHANGES IN THYROID CANCER  
  An increasing body of evidence suggests that epigenetic 
changes (DNA methylation, remodeling and post-
translational modification of chromatin) play important roles 
in thyroid tumorigenesis, as a result of their effects on 
tumor-cell differentiation and proliferation. Epigenetic 
silencing of various thyroid-specific genes has been detected 
in thyroid tumors. These changes can diminish the tumor's 
ability to concentrate radioiodine, which dramatically 
reduces treatment options. Epigenetic changes in tumor- 
promoting and tumor-suppressor genes also contribute to the 
dysregulation of thyrocyte growth and other aspects of 
tumorigenesis, such as apoptosis, motility and invasiveness 
[57,78]. Progress in the field of thyroid cancer genetics has 
produced a novel class of drugs known as ‘targeted 
therapeutics’, which act selectively on cancer cells harboring 
particular genetic aberrations [78], and these agents are 
undergoing clinical testing for the treatment of aggressive 
thyroid carcinomas [79]. The differentiation and 
proliferation properties of thyroid cancer cells are also 
strongly influenced by epigenetic alterations [80], which are 
thought to be equally, if not more, important than mutational 
events in the generation and progression of human cancer 
[81]. Encouraging preliminary results that have been 
obtained with epigenetic treatment strategies in several 
forms of cancer and knowledge of the epigenetic changes 
that occur in thyroid carcinomas (often in combination with 
genetic alterations) is expected to reveal more effective ways 
to treat tumors of this type that fail to respond to currently 
available treatment modalities [81-85]. The cloning of the 
NIS gene has supposed the development of a cytoreducting 
gene therapy based on the transfer of the gene followed by 
the administration of 131I. Recently, the stable transfection 
of the NIS gene over cells of follicular carcinoma (FTC-133) 
without NIS has been achieved, restoring the skills of 131I 
uptake [86-89]. Additionally, in several tumors NIS gene 
transfection has been proposed together with a transfection 
of thyroid peroxidase that might be able to increase the 131I 
uptake in tissue, as well as the amount of irradiation [90]. 
Preclinical studies have furnished convincing evidence that 
deacetylation inhibitors and demethylating agents are 
beneficial in the treatment of thyroid cancer, and these drugs 
are now being tested against metastatic radioiodine-
refractory thyroid carcinomas. Despite promising phase-I 
results, however, histone deacetylases treatment of 16 
patients with differentiated thyroid carcinoma produced no 
partial or complete responses that met response evaluation 
criteria in solid tumors [79] and in a phase-II study, i.v. 
injection of depsipeptide restored radioiodine avidity in 2 of 
the 20 patients treated, but there were no objective responses 
even after 131I treatment [79]. In light of these preliminary 
data, epigenetic strategies seem far less promising than 
approaches that target protein kinases. Indeed, protein kinase 
antagonists have produced decidedly better response rates in 
clinical trials (although they are by no means free of adverse 
effects); however, the safety and efficacy of other HDACi 
and demethylating agents, alone or combined, are still being 
assessed. Until the results of these trials become available, 
research on epigenetic alterations in thyroid cancer must 
continue with the ultimate objective of developing more 
effective treatments for these tumors [81-84].  
OTHER GENETIC ALTERATIONS  
Telomerase 
  Telomeres are repetitive sequences of DNA that 
contribute to its stability, decrease with every cell division, 
and lead to apoptosis. Telomerase is an enzyme with a 
protein and an RNA component that adds repetitions at the 
end of DNA and is not usually present in adult tissues. It has 
been proved that many tumors present telomerase activity 
that immortalizes neoplasic cells. Such cells are determined 
by a polymerase chain reaction and enzyme-linked-
immunoabsorbent assay or by telomere repeat-amplification 
protocol. Telomerase is simply an auxiliary instrument in the 
differential diagnosis of thyroid cancer [90, 91].  
Type I Receptor for Transferrin (TfR1/CD71) 
  Type I receptor for transferrin (TfR1/CD71) is 
overexpressed in several malignant tumors, but no studies 
are available on thyroid carcinomas. Our previous 
comparative analyses of the relative distribution of 
transferrin in benign versus papillary thyroid carcinoma 
tissues highlighted a marked malignancy- associated 
abundance of the molecule. Some results suggest that altered 
expression of TfR1/CD71 may be used as a marker helpful 
in distinguishing papillary thyroid carcinoma from papillary 
hyperplasia and follicular variant from benign follicular-
patterned lesions. Additionally, the present observations 
support the rationale for the use of radiolabeled 
transferrin/transferrin analogs and/or anti-TfR1/CD71 
antibodies for diagnostic and/or radiotherapeutic purposes in 
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  A great number of those that are implicated in 
carcinogenesis or that are expressed in tumors of different 
ways have been used. They have multidisciplinary 
characteristics and are of difficult interpretation given their 
complexity and the variety of results that have been obtained 
[93, 94]. Thus, a growth inhibitor of the signal of 
transduction has been used as the caveolin that intervenes in 
the cellular cycle and also 14-3-3 , a regulator of the 
cellular cycle and the cyclines and kinases dependent of the 
cyclines as well as the non-dependent [95,96]. As a marker, 
S100A9, a binding protein of calcium related to the cell 
differentiation that would be a marker of dedifferentiation 
has also been studied [8]. Different adhesion molecules have 
also been analysed, since these are found overexpressed in 
carcinomas. Furthermore, markers of natural lymphocyte 
killers have been studied, such markers such as CD57, a 
lymphocytes natural killer, whose increased expression 
would be present in cancers [97], as well as that of the 
glucose transporter (GLUT-1) [98]. Other markers such as 
epidermal growth factor receptors, oncoproteins with growth 
capacity and tyrosine kinase activity have been analysed, but 
the results are difficult to interpret and are controversial in 
some cases [99]. Several genes are candidates for the 
tumorigenesis of thyroid cancer and have also been analysed, 
especially those resulting from the microprobe development 
that allows the analysis of multiple genes and from the 
global pattern selection that elucidates which of these genes 
appear in tumor cells; this field is nowadays one that raises a 
great degree of expectation [100]. The recent discovery of 
anaplastic lymphoma kinase (ALK) gene mutations in 
thyroid cancer may rationalize clinical evaluation of ALK 
inhibitors in this setting. In undifferentiated anaplastic 
thyroid cancer, two novel point mutations, C3592T and 
G3602A, found in exon 23 of the ALK gene, with a 
prevalence of 11.11%, but found no mutations in the 
matched normal tissues or in well-differentiated thyroid 
cancers. These two mutations, resulting in L1198F and 
G1201E amino acid changes, respectively, both reside within 
the ALK tyrosine kinase domain where they dramatically 
increased tyrosine kinase activities. Similarly, these 
mutations heightened the ability of ALK to activate the 
phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen- 
activated protein (MAP) kinase pathways in established 
mouse cells. Similar oncogenic properties were observed in 
the neuroblastoma-associated ALK mutants K1062M and 
F1174L but not in wild-type ALK. These findings reveal two 
novel gain of function mutations of ALK in certain, 
undifferentiated anaplastic thyroid cancer and they suggest 
efforts to clinically evaluate the use of ALK kinase inhibitors 
to treat patients who harbor undifferentiated cancers with 
these mutations [101]. The role of the phosphatidylinositol-3 
kinase regulatory subunits in differentiated and 
undifferentiated thyroid carcinomas also in amplifications 
and mutations is also important and the activation of this 
pathway is a contribution in thyroid cancer progression; clear 
understanding of the role played by components of this 
signaling pathway could be important for the understanding 
of thyroid tumor progression and the development of novel 
compounds to be used in clinical trials. The role of -catenin 
and phosphatidylinositol-3 kinase regulatory subunits is 
important either it is in differentiated or in undifferentiated 
thyroid carcinomas [102,103]. Proteomic has been 
introduced recently, though not for the systematic study of 
the samples extracted by FNAB, but its results serve to 
validate different potential markers, confirming in the 
current studies that the best of these would be galectin-3, 
galectin-1 and the protein S100C48 [104]. Regarding 
specific mutations that constituted the panel for thyroid 
cancer diagnostic, RAS, BRAF, RET/PTC, and PAX8/PPAR 
mutations had all a 100% positive predictive value for 
cancer. Patients with these mutations would be candidates 
for total thyroidectomy irrespective of the cytologic 
diagnosis [43].  
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